2020 HFSA Annual Scientific Meeting: Non-CE
Course Details and Faculty Listing

COVID-19: Lessons Learned in Heart Failure and Living with the New Normal

Moderator (Introduction)
P. Luc, University of Ottawa Heart Institute, Ottawa, ON, CANADA.

Acute COVID-19 Cardiovascular Syndrome
N. Hendren; Internal Medicine, University of Texas-Southwestern, Dallas, TX.

RAAS Inhibitor Therapies and Other Core HF Therapies in Heart Failure (during the pandemic and when COVID-19 Positive)
P. Luc, University of Ottawa Heart Institute, Ottawa, ON, CANADA.

Social Distancing, Social Isolation and Heart Failure: Lessons Learned in Regard to Self-Care
D. Davison; Association of American Heart Failure Nurses, Nashville, TN.

Telemedicine in COVID-19: Strengths, Limitations and Innovations Needed
M. Vaduganathan; Brigham and Women's Hospital Heart and Vascular Care, Boston, MA.

Moderator (Panel Q&A)
N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.

Panel Discussion

To Right A Wrong in Heart Failure

Moderator (Introduction)
M. Saltzberg; Medical College of Wisconsin, Milwaukee, WI.

Pathophysiology and Differential Diagnosis of Right Ventricular Dysfunction
M. Jacob; Cleveland Clinic, Cleveland, OH.

Assessment of Right Ventricular Function
K. J. Tedford; Medical University of South Carolina, Charleston, SC.

Medical Optimization of Right Ventricular in HFpEF and HF/LVT
P. Shah; Inova Heart and Vascular Institute, Falls Church, VA.

Device Management in Right Ventricular Failure
R. K. Kapur; Tufts Medical Center, Boston, MA.

Moderator (Panel Q&A)
K. Crespo-Leiro; University Hospital A Coruna, A Coruna Galicia, SPAIN.

Case Study & Panel Discussion

Beyond Socioeconomic & Access to Care: The Clinical Imparative for Understanding Racial HF Differences and Disparities

Moderator (Introduction)
A. A. Morris; Cardiology, Emory University, Atlanta, GA.

Racial Differences in Rates of Heart Failure Hospitalization and Death: A Growing Problem
E. Zanev; David Geffen School of Medicine at UCLA, Los Angeles, CA.

Not Just a Man's Disease: The Disproportionate Burden of Heart Failure in Women of Color
E. Hack; Cleveland Clinic, Cleveland, OH.

Genetic Determinants that Contribute to the Higher Incidence of Heart Failure in Persons of African Ancestry
D. M. McNamara, Sr.; University of Pittsburgh Medical Center, Pittsburgh, PA.

A-HEFTY of A LEFTY? (The Effect of Black Patients in Heart Failure Trials)
S. Lewis; Stanford University Medical Center, Stanford, CA.

Moderator (Panel / Q&A)
C. Yancy; Northwestern University Feinberg School of Medicine, Chicago, IL.

Panelist
K. Bre.Checked; University of Arizona, Tucson, AZ.

Panelists
C. J. Rodriguez; Albert Einstein College of Medicine, Bronx, NY.

Case Study & Panel Discussion

Heart Meets Kidney

Moderator (Introduction)
K. A. Brisco-Bacik; Temple Health & Vascular Institute, Philadelphia, PA.

Latest Insights to Pathophysiology of CKD
K. A. Chen; Division of Cardiovacular Diseases, Mayo Clinic, Rochester, MN.

Diuretic Decongestion Strategies: Which DOSE, Route and Combination?
A. Bagnola; Inova Heart and Vascular Institute, Falls Church, VA.

Cardio-Renal Learnings From New Trials
J. P. Dwyer; Vanderbilt University Medical Center, Nashville, TN.

Non-Medication Based Therapeutic Strategies
J. M. Testani; Yale University, New Haven, CT.

Moderator (Panel / Q&A)
P. McGilough; Baylor Heart & Vascular Hospital, Dallas, TX.

Future HF Trials

Moderator
K. Konstam; Tufts Medical Center, Boston, MA.

Cardiac Myosin Activation with Omapatriz Mecarbit in Systolic Heart Failure
J. R. Teerlink; Cardiology, 111C, San Francisco VAMC/UCSF, San Francisco, CA.

MRP Studies with LC-3 Farnesyltransferase
S. Chong; Vanderbilt University Medical Center, Nashville, TN.

Post-MI studies with SGLT2 inhibitors
J. A. Gutin; Cardiology, Medicine, Women's College Hospital, Toronto, ON, CANADA.

IV Iron Replacement Outcomes Trials
R. J. Tedford; VA Medical Center, San Francisco, CA.

PARADIGM-HF
S. Lewis; Stanford University Medical Center, Stanford, CA.

Moderator (Panel / Q&A)
P. McGilough; Baylor Heart & Vascular Hospital, Dallas, TX.

Panel Discussion

Excellence in Translational Science: Fast Track Discovery to Application

Moderator
K. Konstam; Tufts Medical Center, Boston, MA.

Preamble and Objectives
P. Luc; University of Ottawa Heart Institute, Ottawa Canada, ON.

Technologies to Fast Track Translation - Single Cell Omics for Personalized Medicine
M. Snyder; Stanford University School of Medicine, Palo Alto, CA.

Technologies to Fast Track Translation - Big Data/Deep Modeling of Molecular Interactions
Y. Lightstone; Lawrence Livermore/AXA Collaborative Initiative, Livermore, CA.

Technologies to Fast Track Translation - Power and Pitfalls of AI Applied to ECHO
C. Lam; National Heart Centre, Singapore/Guke-NUS Medical School, Singapore, SINGAPORE.

"Tom Ford" Keynote Lecture: Myosin Myopathies: Pathogenesis and Potential Therapeutics
L. Leinwand; Howard Hughes Medical Institute, Boulder, CO.

Panelists
F. Littman; Tufts Medical Center, Boston, MA.

Panelists
S. Keteyian; Henry Ford Health System, Detroit, MI.

Panelists
J. R. DeBenedictis; Tufts Medical Center, Boston, MA.

Panelists
P. Mather; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Panelists
J. Wilcox; Northwestern University Feinberg School of Medicine, Chicago, IL.

Panelists
J. Howlett; University of Calgary, Calgary, AB, CANADA.

Panelists
N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.

Panelists
M. Vincent; University Hospital A Coruna, A Coruna Galicia, SPAIN.

Update on Medical Treatment Strategies in HF
Supporting the HF Workforce: Optimizing Physical and Mental Wellness Among HF Providers

Presentation Speaker(s)
Moderator (Introductions) A. Moore Gibbs; Altru Health - Sanger Heart & Vascular Institute, Charlotte, NC.
Clinician Well-Being: A Healthy Policy Perspective T. Shanafelt; Stanford Medicine - Weill MD Center, Stanford, CA.
How to Identify and Act on Early Signs of Clinician Burnout C. Sinsky; Sinsky Healthcare Innovations, Philadelphia, PA.
Tips for Healthy Living at Work: Staying Active and Eating Healthy A. Areias; University of Illinois at Chicago, College of Applied Health Sciences, Chicago, IL.
Boutique and Quality of Life Work Among Cardiology Practitioners J. Capadia; Johns Hopkins University, Baltimore, MD.
Role of Professional Societies in Support and Protecting HF Clinicians Against Burnout (Physician) P. Harris; American Medical Association, Washington, DC.
Role of Professional Societies in Support and Protecting HF Clinicians Against Burnout (Nurse) C. Lewis; Vanderbilt University Medical Center, Nashville, TN.

HF and the End of Life: Opportunities for Innovation and Collaboration at the Intersection of Cardiology and Palliative Care

Presentation Speaker(s)
Moderator (Introductions) A. O'Donnell; Department of Cardiology, Boston University School of Social Work, Boston, MA.
Role of Early Palliative Care for Heart Failure: Planning Ahead without Creating Much Ado about Nothing T. Vaharak; Brigham and Women’s Hospital/Boston Veterans Affairs Medical Center, Boston, MA.
Advanced Therapies and Palliative Care: Big Decisions, Big Considerations, Big Feelings H. Warnach; Brigham and Women’s Hospital/Boston Veterans Affairs Medical Center, Boston, MA.
Innovative Partnerships Between Palliative Care and Heart Failure Cardiology: Creating a Team of Teams A. R. Dobble; Palliative Medicine, Cleveland Clinic, Cleveland, OH.
Social Determinants and Financial Considerations at End of Life; In Hospice You Can Keep Doing Everything That Makes You Feel Better – Except For This Long List of Things K. Y. Ambaredekar; University of Colorado, Aurora, CO.
Caregiver Burden in Advanced Heart Failure: The Forgotten R. M. Masterson Cribler; Healthcare Policy & Research, Well Cornell Medicine, New York City, NY.
Moderator (Panel / Q&A) A. S. Lamee; University of Vermont Medical Center, Burlington, VT.

Contemporary Challenges in Heart Transplantation: A New Decade, New Opportunities

Presentation Speaker(s)
Moderator (Introductions) R. Schnorf; Vanderbilt University Medical Center, Nashville, TN.
Time for a Tune-up: Let the Pharmacist under the Hood Before You Hit the Road D. Jennings; Columbia University Medical Center, New York, NY.
Charting the Course: Navigating the New Allocation System to a Successful Transplant R. J. Cogswell; Medicine, University of Minnesota, Minneapolis, MN.
Finding the Right Travel Buddy: When Should the Kidney Come Along for the Ride? S. Solomon; Brigham and Women’s Hospital, Boston, MA.
Check the Tire Pressure! What to do When Your Patient Has Pre-transplant Pulmonary Hypertension A. Guha; Cardiology, Houston Methodist, Houston, TX.
Pumping the Breaks on Bad Antibodies: Contemporary Approaches to Sensitized Heart Transplant Candidates M. Habal; Columbia University, New York, NY.
Moderator (Panel / Q&A) L. Peters; Advanced Heart Failure and Cardiac Transplantation, University of Colorado, Boulder, CO.

Hospitals and Transitions of Care: It Takes A Village

Presentation Speaker(s)
Moderator (Introductions) O. Jackson; Cardiology, Medical University of South Carolina, Charleston, SC.
Inpatient Pathways and Team-Based Care to Improve Post-Discharge Outcomes of Hospitalized Heart Failure Patients S. Hollenberg; Hackensack Meridian University, Hackensack, NJ.
Smoothing Heart Failure Care Transitions: Contemporary Strategies Utilizing Case Managers and APNs N. M. Albert; Cleveland Clinic, Cleveland, OH.
Post the Medications Right: Pharmacists Optimizing GDMT During Transitions of Care V. Siro; University of Illinois at Chicago, Chicago, IL.
Whole Job is An Anyway: Managing Comorbidities Following Heart Failure Discharge S. Mosby; Baylor University Medical Center, Dallas, TX.
The ‘Other’ Transition: When and How to Consider Palliative Care in Patients with Heart Failure J. Rogers; Duke University Health System, Durham, NC.
Moderator (Panel / Q&A) P. Kirkwood; St. Joseph Heritage Healthcare, CA.

JNC New Investigator Award: Basic, Translational and Clinical

Presentation Speaker(s)
Moderator (Introductions) O. Jackson; Cardiology, Medical University of South Carolina, Charleston, SC.
Validation Of Natural Response Prediction Equation In Patients With Acute Decompensated Heart Failure D. Gileason; Yale University School of Medicine, New Haven, CT.
Circulating Protein Biomarkers Associated With Heart Failure With Preserved Ejection Fraction J. Regan; Duke University, Durham, NC.
The Effect Of The Cardiac Myosin Activator, Omecamtiv Mecarbil, On Right Ventricular Structure and Function B. Selmin; Copenhagen; Copenhagen, Denmark.
Race And Sex-specific Population attributable Fractions For Incident Heart Failure: LifeTime Risk Pooling Project N. Simha; Northwestern Feinberg School of Medicine, Chicago, IL.
A Novel Metaanalysis Risk Score Associated With Sex-differences In Heart Failure A. Nayak; Emory University, Atlanta, GA.
Reviewers / Judges (Chair): Jeffrey M. TeSla, Yale University, New Haven, CT
Reviewers / Judges: S. M. Strain; Western University of Health Sciences, Pomona, CA.
Reviewers / Judges: H. M. Vukusich; Brigham and Women’s Hospital Heart and Vascular Center, Boston, MA.
Reviewers / Judges: C. Lewis; Vanderbilt University Medical Center, Nashville, TN.

Nurse Investigator Award: Research and Clinical

Presentation Speaker(s)
Moderator: J. Howie-Esquivel; Charlottesville, VA.
<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhancing Shared Decision Making In A Chronic Population. Use Of An Advance Directive Decision Aid For Patients With Heart Failure And Their Caregivers.</td>
<td>Emily Benton; University of Colorado Denver, CO</td>
<td></td>
</tr>
<tr>
<td>Predictive Model for Risk of 30-Day Rehospitalization Using A Natural Language Processing/machine Learning Approach Among Medicare Patients With Heart Failure</td>
<td>Younseong Kang; University of Utah, Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td>Blacks With Hypertrophic Cardiomyopathy Have Lower Quality Of Life And Exercise Capacity Than Whites</td>
<td>Mia Arabadian; NYU Rory Meyers College of Nursing; New York, NY</td>
<td></td>
</tr>
<tr>
<td>Virtual Outpatient Heart Failure Care - Lessons From The Covid-19 Era</td>
<td>Sharon Upton; University of Utah Health Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td>Reducing Heart Failure Readmissions Through A Shared Medical Appointment</td>
<td>Lisa Filyo; VA, Orlando, FL</td>
<td></td>
</tr>
<tr>
<td>Our Experience With Using Watchpati (Jannar Medical, Ltd.), Home Sleep Testing (tst) For The Diagnosis Of Sleep Apgas In Advanced Heart Failure Patients</td>
<td>Sandra Carey; Baylor Scott and White HCS, Colleyville, TX</td>
<td></td>
</tr>
<tr>
<td>Reviewer/Judge</td>
<td>W. Alonso; College of Nursing, University of Nebraska Medical Cent, Omaha, NE</td>
<td></td>
</tr>
<tr>
<td>Reviewer/Judge</td>
<td>Q. E. Denfeld; School of Nursing, Oregon Health &amp; Science University, Portland, OR.</td>
<td></td>
</tr>
<tr>
<td>Reviewer/Judge</td>
<td>B. Lewis; Vanderbilt University Medical Center, Nashville, TN</td>
<td></td>
</tr>
<tr>
<td>Reviewer/Judge</td>
<td>Z. Billert; University of California, Davis, Davis, CA</td>
<td></td>
</tr>
<tr>
<td>Reviewer/Judge</td>
<td>P. E. Brennan; Transplant, Tampa General Hospital, Tampa, FL</td>
<td></td>
</tr>
<tr>
<td>Friday Plenary: Impact of Music in HF - A Live Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction of Moderators and Panel</td>
<td>B. Bokor; Dallas, TX</td>
<td></td>
</tr>
<tr>
<td>Moderator</td>
<td>M. Rich; Washington University, St. Louis, St. Louis, MI</td>
<td></td>
</tr>
<tr>
<td>Benefits of Listening to Classical Music in Patients with HF: A Randomized Controlled Trial</td>
<td>P. Hauptman; University of Tennessee Knoxville, Knoxville, TN</td>
<td></td>
</tr>
<tr>
<td>Panel</td>
<td>K. Fleming; Soprano Renee Fleming, 't, DC.</td>
<td></td>
</tr>
<tr>
<td>Panel</td>
<td>E. Edwards; National Center for Complementary &amp; Integrative Health, Bethesda, MD.</td>
<td></td>
</tr>
<tr>
<td>Panel</td>
<td>J. Leg; National Center for Complementary &amp; Integrative Health, Bethesda, MD.</td>
<td></td>
</tr>
<tr>
<td>Panel</td>
<td>J. Kulinski; Medical College of Wisconsin, HUB for Collaborative Medicine, Wauwatosa, WI.</td>
<td></td>
</tr>
<tr>
<td>Panel</td>
<td>S. Robb; Indiana University School of Nursing, Indianapolis, IN.</td>
<td></td>
</tr>
<tr>
<td>EMPEROR Reduced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction</td>
<td>M. Packer; Mayo Heart and Vascular Institute, Baydar University Medical Center, Dallas, TX.</td>
<td></td>
</tr>
<tr>
<td>Primary Results with Emphasis on Major Primary and Secondary Endpoints and Safety</td>
<td>M. Packer; Mayo Heart and Vascular Institute, Baydar University Medical Center, Dallas, TX.</td>
<td></td>
</tr>
<tr>
<td>Comparison of Effects of Empagliflozin in Patients with HF With and Without Diabetes</td>
<td>S. Arker; Chantel Medical School of the Humboldt University Berlin, Germany, Berlin, GERMANY.</td>
<td></td>
</tr>
<tr>
<td>Discussion</td>
<td>M. Costanzo; Advocate Heart Institute, Naperville, IL</td>
<td></td>
</tr>
<tr>
<td>Comparison of DAPA-HF and EMPEROR-Reduced</td>
<td>F. Zannad; Hospital Brabois, CIC-P InsrunCHU, Vandoeuvre-Les-Nancy, FRANCE.</td>
<td></td>
</tr>
<tr>
<td>Safety and Clinical Implications</td>
<td>G. Filippatos; University of Athens, Athens, GREECE</td>
<td></td>
</tr>
<tr>
<td>Discussion</td>
<td>N. J. Se Mao; Mayo University School of Medicine, Scottsdale, AZ.</td>
<td></td>
</tr>
<tr>
<td>Moderator (Panel/Q&amp;A)</td>
<td>J. Pedro Ferreira; Centre Hospitalier Universitaire de Nancy, Laxou, FRANCE.</td>
<td></td>
</tr>
<tr>
<td>Case Study &amp; Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of HF in Rural/Frontier Areas: Challenges and Potential Solutions for Clinical Practice and Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction</td>
<td>J. Howie-Esquer; University of Virginia School of Nursing</td>
<td></td>
</tr>
<tr>
<td>Access to care in rural/frontier settings: Current challenges and potential solutions</td>
<td>W. Atorino; University of North Carolina</td>
<td></td>
</tr>
<tr>
<td>QIIMT Implementation in rural/frontier settings: Current challenges and potential solutions</td>
<td>R. Page; University of Colorado</td>
<td></td>
</tr>
<tr>
<td>The importance of health literacy in rural/frontier settings</td>
<td>D. Moser; University of Kentucky College of Nursing</td>
<td></td>
</tr>
<tr>
<td>Clinical Practice Challenges and Needs in Rural/Frontier Settings</td>
<td>L. Wick; University of MN, Duluth, MN.</td>
<td></td>
</tr>
<tr>
<td>Research Challenges and Needs in Rural/Frontier Settings</td>
<td>J. Leen; College of Nursing, Florida State University, Tallahassee, FL</td>
<td></td>
</tr>
<tr>
<td>Moderator (Panel/Q&amp;A)</td>
<td>D. Moser; University of Kentucky, Lexington, KY.</td>
<td></td>
</tr>
<tr>
<td>Case Study &amp; Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocarditis: Management Update</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction</td>
<td>J. Avis; University of Rochester Medical Center, Rochester, NY.</td>
<td></td>
</tr>
<tr>
<td>2020 AHA Scientific Statement on the Management of Fulminant Myocarditis</td>
<td>J. C. Fang; University of Utah, Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td>Cardiac sarcoidosis: A Not So Rare Cause of Cardiomyopathy</td>
<td>N. Zafar; Johns Hopkins, Baltimore, MD.</td>
<td></td>
</tr>
<tr>
<td>Role of MRI and PET Imaging for the Diagnosis of Acute Myocardial Inflammation</td>
<td>W. Blankstein; Brigham and Women's Hospital, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Choice of Mechanical Circulatory Support for Fulminant Myocarditis</td>
<td>H. Vidula; University of Rochester, Rochester, NY.</td>
<td></td>
</tr>
<tr>
<td>Ongoing Trials for Acute Myocarditis and Sarcoidosis</td>
<td>L. Cooper; Mayo Clinic, Jacksonville, FL.</td>
<td></td>
</tr>
<tr>
<td>Moderator (Panel/Q&amp;A)</td>
<td>D. Moser; University of Kentucky, Lexington, KY.</td>
<td></td>
</tr>
<tr>
<td>Case Study &amp; Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unfolding Development in the Care of Patients with TTR Cardiac Amyloidosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction</td>
<td>A. A. Patel; The Cardiovascular Center, Tufts Medical Center, Boston, MA.</td>
<td></td>
</tr>
<tr>
<td>Understanding Cardiac Amyloidosis: Insights from the Bench</td>
<td>K. Alexander; Stanford University, Stanford, CA.</td>
<td></td>
</tr>
<tr>
<td>The Road to Diagnosis: Whom Do I Screen, When Do I Biopsy</td>
<td>B. Sperry; St. Lukes MidAmerica, Kansas City, MO.</td>
<td></td>
</tr>
<tr>
<td>Imaging for Cardiac Amyloidosis: Pearls and Pitfalls</td>
<td>D. Dobrila; Brigham and Women's, Boston, MA.</td>
<td></td>
</tr>
<tr>
<td>Advanced Heart Failure Therapies in the Patient with Cardiac Amyloid</td>
<td>J. Grodin; UT Southwestern, Dallas, TX.</td>
<td></td>
</tr>
<tr>
<td>Current and Emerging Therapies for Transthyretin Amyloid</td>
<td>M. Maurer; Columbia University, New York, NY.</td>
<td></td>
</tr>
<tr>
<td>Practical Tips for Pharmacotherapy Challenges in Transthyretin Amyloid, Including Helping Patients Navigate Access to Therapy</td>
<td>L. West; Cleveland Clinic, Cleveland, OH.</td>
<td></td>
</tr>
<tr>
<td>Moderator (Panel/Q&amp;A)</td>
<td>M. Hana; Cardiology, Cleveland Clinic Foundation, Cleveland, OH.</td>
<td></td>
</tr>
<tr>
<td>Case Study &amp; Panel Discussion</td>
<td>N. Willems; Stanford University Medical Center, Stanford, CA.</td>
<td></td>
</tr>
<tr>
<td>Dangerous Liaisons in Pulmonary Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction</td>
<td>M. A. Simon; University of Pittsburgh, Pittsburgh, PA.</td>
<td></td>
</tr>
<tr>
<td>Case 1: Double Trouble</td>
<td>P. Forha; HFSIA, Northfield, MN.</td>
<td></td>
</tr>
<tr>
<td>Case 2: Double Trouble, Tool and Trouble</td>
<td>B. Alpert; Providence Heart Institute, Portland, OR.</td>
<td></td>
</tr>
<tr>
<td>Panel Discussion and/or Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Panel Member 1</td>
<td>M. Toonkang-Mallard, George Washington University, Washington, DC.</td>
<td></td>
</tr>
<tr>
<td>Panel Member 2</td>
<td>H. Ventura; Ochsner Clinic Foundation, New Orleans, LA.</td>
<td></td>
</tr>
<tr>
<td>Panel Member 3</td>
<td>S. Murali; Allegheny Health Network, Pittsburgh, PA.</td>
<td></td>
</tr>
<tr>
<td>Panel Member 4</td>
<td>M. Kanwar; Allegheny General Hospital, Pittsburgh, PA.</td>
<td></td>
</tr>
<tr>
<td>Structural Interventions for A Failing Heart: A Partnership Between Interventional and HF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>Speaker(s)</td>
<td>Location</td>
</tr>
<tr>
<td>Introduction</td>
<td>J. Rosenthal; Mayo Clinic Arizona, Phoenix, AZ.</td>
<td></td>
</tr>
<tr>
<td>To Clip or Not to Clip: That is the Debate! MitraClip Confirmed</td>
<td>M. Ackermann; University of Pennsylvania, Philadelphia, PA.</td>
<td></td>
</tr>
<tr>
<td>To Clip or Not to Clip: That is the Debate! MitraClip - Need More Data</td>
<td>L. Gurley; University of Michigan, Ann Arbor, MI.</td>
<td></td>
</tr>
<tr>
<td>Percutaneous Tricuspid Valve Interventions: Myth or Reality</td>
<td>S. F. Bolling; Michigan Medicine University of Michigan, Ann Arbor, MI.</td>
<td></td>
</tr>
</tbody>
</table>
Transcatheter Aortic Valve Replacement for Patients with Low Ejection Fraction: Should It be Used for the Low Flow, Low Gradient State?  M. Reardon; Houston Methodist Hospital, Houston, TX.

Atrial unloading to treat ventricular dysfunction: conceptual framework and therapies  D. Burkhoff; Cardiovascular Research Foundation, New York, NY.

Moderator (Panel)  N. Ureti; Columbia Presbyterian University, New York, NY.

Case Study & Panel Discussion

Advances in the Treatment of Monogenic Cardiomyopathies

Presentation

Speaker(s)

Moderator (Introductions)  M. Mehra; Harvard University, Boston, MA.

Hypertrophic Cardiomyopathy - Out with the Old

J. Tardiff; University of Arizona, Tucson, AZ.

Dilated Cardiomyopathy - Personalizing Common Treatments

K. Sultan; Stanford University, Stanford, CA.

Risk Stratification and Management of Arrhythmogenic Cardiomyopathies

M. Maron; Tufts Medical Center, Boston, MA.

Practical Approaches to Patients Suspected of Genetic Cardiomyopathies

K. Horshberger; Ohio State University, Columbus, OH.

DISCUSSANT - Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial

K. Sharma; Medicine, Johns Hopkins Hospital, Baltimore, MD.

Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial

Joao Pedro Ferreira; CIC-P Nancy, Vandoeuvre-les-Nancy, France

DISCUSSANT - Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) J. J. McMurray; Institute of Cardiovascular and Medical Sciences-, Glasgow, BC.

Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)

E. J. McMurray; Institute of Cardiovascular and Medical Sciences-, Glasgow, BC.

DISCUSSANT - Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) J. J. McMurray; Institute of Cardiovascular and Medical Sciences-, Glasgow, BC.

Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Empirical Trials

S. Gottlieb; Medicine, Johns Hopkins Hospital, Baltimore, MD.

DISCUSSANT - Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Empirical Trials

S. Gottlieb; Medicine, Johns Hopkins Hospital, Baltimore, MD.

Case Study & Panel Discussion

President Reception and Award Recognition

Knowing It When You See It: Defining Congestion and Decongestion

Presentation

Speaker(s)

Moderator (Introductions)  J. Thibodeau; UT Southwestern, Dallas, TX.

Wet and Upset - Why Congestion Is Such a Big Deal In Heart Failure

S. Feiker; Duke Clinical Research Institute, Durham, NC.

Fat, Lean, and Related - Malnutrition, Heart Failure, and the Cardiac Metabolome

W. L. Miller; Cardiovascular, Mayo Clinic, Rochester, MN.

The Ups and Downs of Natriuretic Peptides for Detecting Congestion

K. Adams, Jr.; University of North Carolina at Chapel Hill, Chapel Hill, NC.

Patients - You Can't Escape A Visit to the Doctor Just Yet

M. Drainez; UT Southwestern, Dallas, TX.

Trading In My Stethoscope for A Laptop - We Are Better Off Using Devices To Assess Congestion In Our Patients

A. B. Miller; Cardiology, University of Florida- Shands Jacksonville, Jacksonville, FL

Case Study & Panel Discussion

When Social Determinants Health Collide with HF Care and Treatment Decisions

Presentation

Speaker(s)

Moderator (Introductions)  K. A. Sethares; Adult and Child Nursing, University of Massachusetts Dartmouth, North Dartmouth, MA.

Implicit and Explicit Bias In Medical Decision-Making

C. Capers, IV; Ohio State University Medical Center, Columbus, OH.

Racial/Ethnic Disparities In Transplant and LVAD Candidacy

K. Breathe; Arizona University, Arizona, AZ.

Gender Disparities In Transplant and LVAD Candidacy

K. A. Morris; Cardiology, Emory University, Atlanta, GA.

Psychosocial Economic Determinants of Advanced Heart failure and Treatment Outcomes: How Its Appropriate address and Factor Into Candidacy

K. L. Grady; Northwestern University, Philadelphia, PA.

Advanced Heart failure treatment complications: How the sausage is Made, and How We Can Make It Even Better

P. Khanzode; University of Colorado, Aurora, CO

Case Study & Panel Discussion

New Data and Learnings from VICTORIA Trial
<table>
<thead>
<tr>
<th>Case 1 - Remote Monitoring During COVID-19</th>
<th>Ambulatory Pulmonary Artery Pressure Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. T. Williams; Henry Ford Hospital, Detroit, MI.</td>
<td></td>
</tr>
<tr>
<td>A. J. Hicks, III; Baylor Scott &amp; White, Round Rock, TX.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Case 2 - Remote Monitoring During COVID-19</th>
<th>Electronic remote monitoring interfaces for VAD Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. Klein; UCSF, San Francisco, CA.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Case 3 - Remote Monitoring During COVID-19</th>
<th>Intrathoracic impedance monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Fine; University of Colorado, Denver, CO.</td>
<td></td>
</tr>
<tr>
<td>S. Hall; Baylor Scott &amp; White Advanced Heart Failure Clinic, Dallas, TX.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Case 4 - Remote Monitoring During COVID-19</th>
<th>Remote cardiac examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. J. Sauer; Henry Ford Hospital, Detroit, MI.</td>
<td></td>
</tr>
<tr>
<td>D. Laperle; Henry Ford Hospital, Detroit, MI.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Discussant - Wrap Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Breathell; University of Arizona, Tucson, AZ.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Panelist</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Psotla; Inova Heart and Vascular Institute, Falls Church, VA.</td>
</tr>
<tr>
<td>T. Alasy; Emory University, Atlanta, GA.</td>
</tr>
<tr>
<td>L. Le; Ekos, Charlotte, NC.</td>
</tr>
</tbody>
</table>

### Women and Gender Influences in Heart Failure

**Presentation Speaker(s)**

**Moderator (Introductions)**, M. Moges; Vanderbilt University School of Nursing, Nashville, TN.

**Women and Gender Influences in Heart Failure**

J. E. Ho; Massachusetts General Hospital, Boston, MA.

**Sex Differences in Cardiomyopathy**

M. Bloom; Stony Brook University, New York, NY.

**Are There Sex Differences in Heart Failure Treatments? Medications, Mechanical Circulatory Support and Transplantation**

E. M. DeFilippis; Columbia University Irving Medical Center, New York, NY.

**Heart Failure Treatment in Women: Exercise and Cognitive Behavior Therapy - What Works?**

R. Gary; Emory University, Atlanta, GA.

**Heart Failure Across the Pregnancy Continuum: A Rising Concern**

J. Briller; University of Illinois, Chicago, IL.

**Moderator (Panel / Q&A)**, B. Mohammed; Medstar Heart and Vascular Institute, Washington, DC.

**Panel Discussion / Q&A**

### Understanding Heart Failure with Recovered Ejection Fraction

**Presentation Speaker(s)**

**Moderator (Introductions)**

E. Shio; Tufts University, Maine Medical Center, Portland, ME.

**Resynchronization Super-Responders: Who, Why and What Next?**

K. Kaha; Columbus, OH.

**Prioritizing Polypharmacy in Recovered Ejection Fraction**

W. Tang; Cleveland Clinic, Cleveland, OH.

**Recovering Cardiac Function After Viral Myocarditis: Who, Why, and What Are We Going Learning from COVID-19?**

J. Pinney; University of Chicago, Chicago, IL.

**Moderator (Panel/Q&A)**

K. B. Margules; University of Pennsylvania School of Medicine, Philadelphia, PA.

**Panel Discussion/Q&A**

### Integrated Omics in Heart Failure: Precision Medicine Highlights for HF Clinicians and Scientists

**Presentation Speaker(s)**

**Moderator (Introductions)**

M. Piano; Vanderbilt University, Nashville, TN.

**To Screen or Not to Screen: Approach to Clinical Genetic Testing in Patients with Heart Failure**

A. Owens; University of Pennsylvania, Philadelphia, PA.

**Proteomics: From Discovery to Validated Biomarkers**

M. Nayor; Massachusetts General Hospital, Boston, MA.

**Understanding the Role of the Gut Microbiome in Heart Failure**

W. Tang; Cleveland Clinic, Cleveland, OH.

**Pharmacogenomics: Are We Ready for Prime Time?**

D. Laperle; Henry Ford Hospital, Detroit, MI.

**The Case for Diversity to Enhance the Impact of Precision Medicine Research**

J. Ford; National Human Genome Research Institute, Bethesda, MD.

**Moderator (Panel / Q&A)**

J. Luzum; University of Michigan, Ann Arbor, MI.

**Panel Discussion/Q&A**

### The Intersection of Cardiomyopathy and Advanced Heart Failure: From Stage A to D

**Presentation Speaker(s)**

**Moderator (Introductions)**

D. Lenihan; Washington School of Medicine at St. Louis, St. Louis, MO.

**Building a Successful Cardio-Oncology Program**

D. Durand; MD Anderson Cancer Center, Houston, TX.

**Screening for Cardiotoxicity; Imaging? Biomarkers? or None at All**

A. Lai; Memorial Sloan Kettering Cancer Center, Manhattan, NY.

**What’s Old, New and Emerging About Cardiotoxicity?**

A. Barac; Medstar Washington Hospital Center, Washington, DC.

**Immunotherapy and Cardiac Dysfunction: From Mechanisms to Therapy**

L. Moshahi; Vanderbilt University Medical Center, Nashville, MI.

**Advanced Cardiomyopathy: What About LVAD and Heart Transplant Patients?**

A. Nohria; Brigham and Women’s Hospital, Boston, MA.

**Moderator (Panel/Q&A)**

A. Nohria; Brigham and Women’s Hospital, Boston, MA.

**Panel Discussion/Q&A**

### Afibrillation and Heart Failure: The Beat Goes On

**Presentation Speaker(s)**

**Moderator (Introductions)**

E. M. DeFilippis; Columbia University Irving Medical Center, New York, NY.

**Cardiomyopathy or Atrial Myopathy: Understanding Pathophysiology**

A. Ducharme; Medicine, Montreal Heart Institute, Montreal, QC, CANADA.

**Comparing and Contrasting the US and Canadian Guidelines (Rate/Rhythm/Ablation)**

J. Andrade; Vancouver Coastal Health, Vancouver, BC, CANADA.

**Atrial Fibrillation and Heart Failure: From Mechanisms to Therapy**

K. Breathell; University of Arizona, Tucson, AZ.

**Moderator (Panel / Q&A)**

J. Luzum; University of Michigan, Ann Arbor, MI.

**Panel Discussion / Q&A**

### Implementation: Systematic Strategies of Improving Care and Outcomes

**Presentation Speaker(s)**

**Moderator (Introductions)**

N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.

**Overcoming Clinical Inertia in Use and Dosing of GDMT**

S. Greene; Duke University School of Medicine, Durham, NC.

**How to Test for Variability and Other New Therapies into Clinical Use**

J. Andrade; Vancouver Coastal Health, Vancouver, BC, CANADA.

**Implementing Patient Reported Outcome Measures in Clinical Practice**

K. Breathell; University of Arizona, Tucson, AZ.

**Health Care Policies that Could Incentivize Implementation in HF**

S. Pinney; University of Chicago, Chicago, IL.

**Moderator (Panel / Q&A)**

J. Luzum; University of Michigan, Ann Arbor, MI.

**Panel Discussion / Q&A**

### Clinical-Pathological Cases (CPG): Stump the Professor

**Presentation Speaker(s)**

**Moderator**

M. Drazner; UT Southwestern, Dallas, TX.

**Case**

A. Lai; Memorial Sloan Kettering Cancer Center, Manhattan, NY.

**PROFESSOR Panelists**

B. Greenberg; University California San Diego, La Jolla, CA.

**PROFESSOR Panelists**

M. Konstam; Tufts Medical Center, Boston, MA.

**PROFESSOR Panelists**

K. Breathell; University of Arizona, Tucson, AZ.
**The Economics of Heart Failure – Exploring Social Determinants and Financial Burden in the Care of Patients with HF**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial Toxicity: What is it and What Are the Implications?</td>
<td>K. Nasir; Houston Methodist, Houston, TX</td>
</tr>
<tr>
<td>Assessment of Financial Burden and Its Impact on Health Outcomes</td>
<td>S. D. Slavin; Medicine, Brigham and Women’s Hospital, Boston, MA</td>
</tr>
<tr>
<td>Intersection of Financial Burden with Health Disparities</td>
<td>C. W. Yancy; Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>The Economics of Advanced Therapies</td>
<td>L. Davis; University of North Carolina, Chapel Hill, NC</td>
</tr>
</tbody>
</table>

**Panel Discussion / Q&A**

<table>
<thead>
<tr>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Heidenreich; Stanford VA Palo Alto Medical Center, Palo Alto, CA</td>
</tr>
<tr>
<td>N. Sweitzer; University of Arizona, Tucson, AZ</td>
</tr>
</tbody>
</table>

**Dr. Alexa is In: Leveraging Technology in Heart Failure Care**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Future of Wearables in Patients with Heart Failure</td>
<td>A. D. DeVore; Duke University Medical Center, Durham, NC</td>
</tr>
<tr>
<td>Always Watching: Remote Monitoring</td>
<td>M. Fraser; University of Minnesota, Minneapolis, MN</td>
</tr>
<tr>
<td>Beyond the After-Visit Summary to Educate and Engage Patients</td>
<td>E. Kellison; CHI Franciscan Health, Tacoma, WA</td>
</tr>
<tr>
<td>Information Dissemination in the Era of Facebook and Twitter</td>
<td>M. Kittleson; Cedars-Sinai California Heart Center, Beverly Hills, CA</td>
</tr>
</tbody>
</table>

**Panel Discussion / Q&A**

<table>
<thead>
<tr>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty</td>
</tr>
</tbody>
</table>

**Research Network Update**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HF Collaboratory/HSFA Joint Site Base Research Awards</td>
<td>C. O’Connor; Inova, Falls Church, VA</td>
</tr>
<tr>
<td>Trial Conduct in the Era of COVID-19 and Beyond: Industry Trial</td>
<td>F. I. Malik; Cytokinetics, San Francisco, CA</td>
</tr>
<tr>
<td>Trial Conduct in the Era of COVID-19 and Beyond: NIH Trial</td>
<td>W. Y. Abraham; The Ohio State University Wexner Medical Center, Columbus, OH</td>
</tr>
<tr>
<td>Best Practices During COVID-19: Remote Monitoring and End Points</td>
<td>C. O’Connor; Inova, Falls Church, VA</td>
</tr>
</tbody>
</table>

**Case Study & Panel Discussion**